Keen Vision Acquisition Corporation ( (KVAC) ) has shared an announcement.
Keen Vision Acquisition Corporation (KVAC) has entered into a merger agreement with clinical-stage biotech company Medera Inc., which will result in Medera being listed on NASDAQ. The deal values Medera at approximately $622.6 million, with Medera’s founders committing $22.6 million and existing shareholders rolling 100% of their equity. The proceeds will accelerate three advanced clinical programs focused on gene therapy for heart diseases. The combined entity aims to provide innovative therapies for difficult-to-treat cardiovascular diseases, leveraging Medera’s proprietary platforms for disease modeling and drug discovery. The transaction is set to close in the fourth quarter of 2024, with Medera having a minimum of $40 million in available liquidity as a closing condition.
See more data about KVAC stock on TipRanks’ Stock Analysis page.
